neurofibroma – Talk Bio

Actionable Insights Powered by AI

FDA Approves SpringWorks’ Gomekli for Adult and Pediatric NF1-PN Patients

Gomekli, mirdametinib, neurofibromatosis type 1, plexiform neurofibromas, FDA approval, SpringWorks Therapeutics, MEK inhibitor